Jeff Yass’s Global Blood Therapeutics, Inc. GBT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-235,800
| Closed | -$16.1M | – | 14655 |
|
|
2022
Q3 | $16.1M | Buy |
235,800
+125,200
| +113% | +$6.9M | ﹤0.01% | 1624 |
|
|
2022
Q2 | $3.53M | Buy |
110,600
+23,200
| +27% | +$679K | ﹤0.01% | 3787 |
|
|
2022
Q1 | $3.03M | Buy |
87,400
+26,700
| +44% | +$798K | ﹤0.01% | 4599 |
|
|
2021
Q4 | $1.78M | Sell |
60,700
-30,000
| -33% | -$929K | ﹤0.01% | 5788 |
|
|
2021
Q3 | $2.31M | Buy |
90,700
+49,500
| +120% | +$1.45M | ﹤0.01% | 5529 |
|
|
2021
Q2 | $1.44M | Sell |
41,200
-44,500
| -52% | -$1.74M | ﹤0.01% | 6755 |
|
|
2021
Q1 | $3.49M | Sell |
85,700
-72,400
| -46% | -$3.33M | ﹤0.01% | 4642 |
|
|
2020
Q4 | $6.85M | Buy |
158,100
+55,200
| +54% | +$2.72M | ﹤0.01% | 2970 |
|
|
2020
Q3 | $5.67M | Sell |
102,900
-71,600
| -41% | -$4.55M | ﹤0.01% | 2892 |
|
|
2020
Q2 | $11M | Sell |
174,500
-19,000
| -10% | -$1.3M | ﹤0.01% | 2030 |
|
|
2020
Q1 | $9.89M | Sell |
193,500
-247,000
| -56% | -$16.5M | ﹤0.01% | 1752 |
|
|
2019
Q4 | $35M | Buy |
440,500
+254,900
| +137% | +$15.1M | 0.01% | 1021 |
|
|
2019
Q3 | $9.01M | Sell |
185,600
-140,200
| -43% | -$7.31M | ﹤0.01% | 2093 |
|
|
2019
Q2 | $17.1M | Sell |
325,800
-116,800
| -26% | -$6.71M | 0.01% | 1396 |
|
|
2019
Q1 | $23.4M | Buy |
442,600
+68,900
| +18% | +$3.39M | 0.01% | 1075 |
|
|
2018
Q4 | $15.3M | Sell |
373,700
-17,700
| -5% | -$663K | 0.01% | 1252 |
|
|
2018
Q3 | $14.9M | Sell |
391,400
-608,300
| -61% | -$26.9M | ﹤0.01% | 1571 |
|
|
2018
Q2 | $45.2M | Buy |
999,700
+679,400
| +212% | +$30.9M | 0.02% | 743 |
|
|
2018
Q1 | $15.5M | Sell |
320,300
-17,500
| -5% | -$976K | 0.01% | 1419 |
|
|
2017
Q4 | $13.3M | Buy |
337,800
+233,800
| +225% | +$8.73M | ﹤0.01% | 1585 |
|
|
2017
Q3 | $3.23M | Sell |
104,000
-9,500
| -8% | -$267K | ﹤0.01% | 3117 |
|
|
2017
Q2 | $3.1M | Sell |
113,500
-210,700
| -65% | -$6.27M | ﹤0.01% | 3091 |
|
|
2017
Q1 | $11.9M | Buy |
324,200
+291,700
| +898% | +$7.35M | 0.01% | 1468 |
|
|
2016
Q4 | $470K | Sell |
32,500
-82,200
| -72% | -$1.44M | ﹤0.01% | 7127 |
|
|
2016
Q3 | $2.64M | Buy |
114,700
+101,700
| +782% | +$1.94M | ﹤0.01% | 3094 |
|
|
2016
Q2 | $216K | Sell |
13,000
-3,600
| -22% | -$72.6K | ﹤0.01% | 7485 |
|
|
2016
Q1 | $263K | Buy |
+16,600
| New | +$295K | ﹤0.01% | 7479 |
|
Other funds holding GBT
Jeff Yass's GBT Position: Q4 2022 in Review
Jeff Yass sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2022, closing a stake of 47,540 shares — an estimated $3.24M sold.
Jeff Yass first reported a position in GBT in Q3 2015 and held it in 21 quarters. The position peaked at $11.7M in Q2 2019. 2 funds tracked by Wall St. Rank hold GBT as of Q4 2022.
- Jeff Yass reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
- Jeff Yass sold 47,540 Global Blood Therapeutics, Inc. shares in Q4 2022, an estimated $3.24M.
- Jeff Yass first reported a position in Global Blood Therapeutics, Inc. in Q3 2015 and held it in 21 quarters.
- Jeff Yass's Global Blood Therapeutics, Inc. position peaked at $11.7M in Q2 2019.
- 2 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2022.
Based on Susquehanna International Group's 13F filing for Q4 2022, filed 14 Feb 2023.